Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 7889-7896

  Hainsworth, John D ^a   Sosman, Jeffrey A ^b   Spigel, David R ^b   Edwards, Donna L ^b   Baughman, Cara ^b   Greco, Anthony ^b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ERLOTINIB; INTERFERON; INTERLEUKIN 2; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMORRHOID HEMORRHAGE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NEUROPATHY; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RASH; SKIN TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUMOR; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ADMINISTRATION, ORAL; ADULT; AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 30944452354     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.8234     Document Type: Article

References (34)

1. Yagoda A, Abi-Bached B, Petrylak D: Chemotherapy for advanced renal cell carcinoma: 1983-1993. Semin Oncol 22:42-52, 1995
2. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 163:408-416, 2000
3. DeMulder PH, Weissbach L, Jakse G, et al: Gemcitabine: A phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 37:491-495, 1996
4. Walpole ET, Dutcher JP, Sparano J, et al: Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2. J Immunother 13:275-285, 1993
5. Mertens WC, Eisenhauer EA, Jolivet J, et al: Docetaxel in advanced renal carcinoma: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5:185-191, 1994
6. Fisher RI, Coltman CA Jr, Doroshow JH, et al: Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: A phase II clinical trial. Ann Intern Med 108:518-523, 1988
7. Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338:1272-1278, 1998
8. Ilson DH, Motzer RJ, Kradin RL, et al: A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J Clin Oncol 10:1124-1130, 1992
9. Geertsen PF, Hermann GG, van der Maase H, et al: Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: A single-center phase II study. J Clin Oncol 10:753-759, 1992
10. Gnarra JR, Tory K, Weng Y, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90, 1994
11. Latif F, Tory K, Gnarra J, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-13120, 1993
12. Iliopoulos O, Kaelin WG Jr: The molecular basis of von Hippel-Lindau disease. Mol Med 3:289-293, 1997
13. Iliopoulos O, Levy AP, Jiang C, et al: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93:10595-10599, 1996
14. Mukhopadhyay D, Knebelmann B, Cohen HT, et al: The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17:5629-5639, 1997
15. Ananth S, Knebelmann B, Gruning W, et al: Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 59:2210-2216, 1999
16. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
17. Riedel F, Gotte K, Li M, et al: EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. Int J Oncol 21:11-16, 2002
18. Ciardiello F, Caputo R, Bianco R, et al: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-1465, 2001
19. Viloria-Petit A, Crombet T, Jothy S, et al: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61:5090-5101, 2001
20. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
21. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Mantel N, Haenszel W: Statistical aspects of the analyses of data from the retrospective study of disease. J Natl Cancer Inst 27:719-748, 1959
24. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cancer. J Clin Oncol 17:2530-2540, 1999
25. Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2001
26. Motzer RJ, Rini BI, Michaelson MD, et al: SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. Proc Am Soc Clin Oncol 23:381, 2004 (abstract 4500)
27. Ratain MJ, Flaherty KT, Stadler WM, et al: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other refractory solid tumors in a phase II randomized discontinuation trial. Proc Am Soc Clin Oncol 23:381, 2004 (abstract 4501)
28. Dawson M, Quo C, Zak R, et al: A phase II trial of ZD1839 in stage IV and recurrent renal cell carcinoma. Proc Am Soc Clin Oncol 22:404, 2003 (abstract 1623)
29. Jermann M, Joerger M, Pless M, et al: An open-label phase Il trial to evaluate the efficacy and safety of gefitinib in patients with locally advanced, relapsed or metastatic renal cell cancer. Proc Am Soc Clin Oncol 22:418, 2003 (abstract 1681)
30. Drucker BJ, Schwartz L, Marion S, et al: Phase II trial of ZD1839 (Iressa), an EGF receptor inhibitor, in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 21:181a, 2002 (abstract 720)
31. Gunnett K, Motzer R, Amato R, et al: Phase II study of anti-epidermal growth factor receptor (EGFR) antibody C225 alone in patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 18:467a, 1999 (abstract 1501)
32. Beeram M, Rowinsky EK, Weiss GR, et al: Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic and biological correlative study with FDG-PET imaging. Proc Am Soc Clin Oncol 23:207, 2004 (abstract 3050)
33. Bergers G, Song S, Meyer-Morse IM, et al: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295, 2003
34. Herbst RS, Johnson DH, Mininberg E, et al: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination wit the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:2544-2555, 2005